Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals (CPRX) has settled patent litigation with Lupin Pharmaceuticals, securing protection for its key drug, Firdapse, from generic competition in the U.S. until February 25, 2035. This agreement is crucial as Firdapse is CPRX's primary revenue driver, accounting for 62% of 2024 sales and $168.6 million in H1 2025, safeguarding a significant portion of its top-line from generic erosion. While this resolves one major threat, the company still faces active patent litigation concerning Firdapse with Hetero, and its other marketed drug, Fycompa, faces patent expiry in 2025/2026.

Analysis

Catalyst Pharmaceuticals (CPRX) has materially improved its long-term outlook by settling patent litigation with Lupin, thereby preventing a generic version of its key drug, Firdapse, from entering the U.S. market until February 25, 2035. This development is critical for the company, as Firdapse constitutes its primary revenue driver, accounting for 62% of its net product sales in 2024 and generating $168.6 million in revenue in the first half of 2025. While this settlement, which follows similar resolutions with Teva and Inventia, significantly de-risks a core asset, an ongoing patent dispute with Hetero remains an unresolved threat to Firdapse's exclusivity. Furthermore, the company faces a near-term headwind with its other marketed drug, Fycompa, whose patents are set to expire in 2025 and 2026, which is expected to cause a significant sales decline due to generic competition. Despite this positive legal resolution for Firdapse, Catalyst's stock has underperformed its industry year-to-date, with a 1.2% loss compared to the industry’s 10.2% growth, suggesting the market had priced in significant litigation risk that may now be reconsidered.

Key Decisions for Investors

• Consider the settlement a significant de-risking event for CPRX, as it secures over a decade of market exclusivity for its primary revenue source, Firdapse, potentially resolving a key overhang that has contributed to the stock's recent underperformance.
• Monitor the ongoing patent litigation against Hetero, as it represents the remaining material risk to Firdapse's market exclusivity and the company's primary cash flow.
• Factor in the expected revenue decline from the drug Fycompa due to patent expirations in 2025 and 2026, which heightens the company's dependence on the Firdapse franchise and its newly acquired asset, Agamree, for future growth.